ZOLL

ZOLL LifeVest®

20+ years of clinical evidence **you can trust**

INFORMATION FOR MEDICAL PROFESSIONALS

1M+ patients protected

LifeVest® protects patients at risk of sudden cardiac death (SCD), when a patient's condition is changing and permanent SCD risk has not been established. LifeVest allows physicians time to assess their patients' long-term arrhythmic risk and make appropriate plans.

LifeVest has been proven safe and effective in extensive clinical research and real-world use across more than one million patients.

Consistent first-shock success rate of >97% in clinical research and real-world use[1–4]

75% reduction in mortality at 90 days in patients who wore LifeVest in a peer-reviewed RCT[5]

96% one-year survival across all patients in a study of 2,000 U.S. patients[6]

Continuous innovation

Over the years, ZOLL® has focused on monitor and garment innovation to optimize patient comfort without compromising performance. **As a result, in real-world use, patient compliance with LifeVest is extremely high with a median wear time of 23.4+ hours per day.**[7,8]

Light, breathable cloth garment

- Worn under the clothing, directly against the patient's skin
- Available in a wide range of sizes, fitting patients from 26" to 56"

Dry, non-adhesive electrodes and therapy pads

- Designed to detect certain life-threatening rapid arrhythmias and deliver appropriate treatment

Monitor

- Continuously monitors the patient's heart and is designed to alert the patient and bystanders if a treatment shock is imminent
- Large interactive touch screen communicates key device information to patients
- Response buttons allow a conscious patient to delay treatment

Advanced algorithm

The LifeVest TruVector™ detection algorithm uses a combination of heart rate, morphology, stability and onset criteria to quickly and accurately detect ventricular tachycardia (VT) and ventricular fibrillation (VF) at a default VT threshold of 150 bpm.

	SENSITIVITY	SPECIFICITY
VT	97%	100%
VF	100%	100%

Sensitivity and specificity within 60 seconds of event detection[9]

In 2018, Advanced Arrhythmia Discrimination (AArD) technology, built with machine learning to enhance arrhythmia classification, was added to the LifeVest TruVector™ algorithm as an additional discriminator to further reduce an already low rate of inappropriate shocks and false detections.[2] **As a result, the majority of LifeVest patients experienced zero false alarms at 90 days.[10]**



Timely defibrillation

TruVector with AArD ensures rapid identification and treatment of ventricular events. In a typical situation, the entire event, from detecting VT/VF to automatically delivering a shock, occurs in about one minute or less.

Default response times are: 60s for VT and 25s for VF. Conscious patients may use the LifeVest response buttons at any time to prevent unnecessary shocks.

Example Detection and Treatment Determination Sequence for VF



** If VF is confirmed and device determines treatment shock is needed*

Insight for better outcomes

Through the ZOLL Patient Management (ZPM) Network, LifeVest combines sudden cardiac death protection with better insight[1,11] providing the opportunity to impact treatment for all your LifeVest patients.

Patients who wear LifeVest could benefit from the therapy, whether from defibrillation or from biometric data captured by the device, with 1 in 14 patients experiencing an arrhythmia requiring clinical intervention while wearing LifeVest.[1]



Monitor Heart Rate
Review weekly, daily, and 5-minute average trends.

Conduct a WalkTest®
Measure distance and heart rate—review results from anywhere.

See Body Position
See patient's angle—upright, reclined, or lying—over time.

Review ECG Recordings
ZOLL's new ECG Classifier utilizes AI to highlight the most clinically relevant ECG recordings.

Review Activity Trends
Patient movement is displayed in steps per day.

Prescribe a Health Survey
Get patient-reported feedback daily or weekly.

To learn more or request a demo, talk to your ZOLL representative.
lifevestinsight.com

Customized to fit your workflow

A ZOLL representative is available to assist your team to customize setup of your ZPM network account so that your practice has access to biometric and arrhythmic data that may be meaningful to your patients' care.



All patient data shown are fictitious and for informational purposes only.

We are continuously updating our products and systems, therefore the appearance of some screens may vary in the ZPM Network portal. For any questions, contact your representative.

Tailor Alerts

Streamline data review by setting alerts for clinical events that may inform patient care.

- Automatic and patient-initiated ECG recordings
- High-trending heart rates
- LifeVest-guided WalkTest

See Opportunities for Action

Biometric data and ECG recordings captured by LifeVest may inform critical treatment decisions and help you achieve a range of treatment goals:

- Optimization of medical therapy
- Timely clinical interventions
- Data-driven patient appointments

To learn more or request a demo, talk to your ZOLL representative.
lifevestinsight.com

Support for your patients

ZOLL is committed to providing patients with easy access to LifeVest, regardless of insurance coverage or income level. We've spent 20+ years building relationships and programs to ensure patients can receive the LifeVest protection they need.

In-person, remote, and digital options ensure that you and your patients are supported every step of the way:

- The largest team of patient service representatives with patient care backgrounds for in-person patient training and support
- 24/7 multilingual support is available to clinicians and patients
- The LifeVest patient app provides patients with tips for wearing and interacting with LifeVest and allows them to review their usage time and activity as they work towards their recovery goals.

100%

100% Medicare Part B coverage and State Medicaid access

>98% of people have in-network commercial access to LifeVest

ZOLL® offers a range of financial plans & programs so all at-risk patients have an option to get LifeVest

Contact ZOLL 24 hours a day, 7 days a week

For LifeVest customer support, technical support or medical orders, please call **800.543.3267**

LifeVest medical orders and supporting documentation can be faxed to **866.567.7615**

For more LifeVest information, please visit **cardiac.zoll.com** or email **LifeVest.Info@zoll.com**

Access LifeVest patient data and e-Order through **zpm.zoll.com**

1 Kutyifa V, Moss AJ, Klein H, et al. Use of the wearable cardioverter defibrillator in high-risk cardiac patients: Data from the prospective registry of patients using the wearable cardioverter defibrillator (WEARIT-II Registry). Circulation 2015;132(17):1613–1619.

2 Data on file, 90d0241_a01. Report of AArD Performance during 2019.

3 Data on file, 90a0061_a01_revb. Clinical Evaluation Report for LifeVest Wearable Defibrillator, Model 4000, 2021.

4 Chung MK, Szymkiewicz SJ, Shao M, Zishiri E, Niebauer MJ, Lindsay BD, & Tchou PJ (2010). Aggregate national experience with the wearable cardioverter-defibrillator: Event rates, compliance, and survival. Journal of the American College of Cardiology, 56(3), 194–203.

5 Olgin JE, Lee BK, Vittinghoff E, et al. Impact of wearable cardioverter-defibrillator compliance on outcomes in the VEST trial: As-treated and per-protocol analyses. J Cardiovasc Electrophysiol 2020;1–10. doi.org: 10.1111/jce.14404.

6 Kutyifa V, Moss A, Klein H, et al. One-year follow-up of the prospective registry of patients using the wearable defibrillator (WEARIT-II Registry). Pacing Clin Electrophysiol. 2018;1–7. doi.org: 10.1111/pace.13448.

7 Data on file, 90d0258_a01. 2021 Commercial Compliance Analysis.

8 David Duncker, Eloi Marijon, Marco Metra, et al. Sudden cardiac death in newly diagnosed non-ischaemic or ischaemic cardiomyopathy assessed with a wearable cardioverter-defibrillator: the German nationwide SCD-PROTECT study, European Heart Journal, 2025; ehaf668, doi.org: 10.1093/eurheartj/ehaf668.

9 Pre-clinical test data on file at ZOLL as of January 2010.

10 Arkles J, Delaughter C, D'Souza B. A novel artificial intelligence based algorithm to reduce wearable cardioverter-defibrillator alarms. J Interv Cardiac Electrophysiol. 2023. doi.org: 10.1007/s10840-023-01497-w.

11 Jungbauer CJ, Maier LS, Emoto K, et al. Achieving Guideline-Directed Heart Rate Control Early Posthospitalization, Am J of Cardiology, 2019.

ZOLL®